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Abstract
 
The pilin glycoprotein (PilE) is the main building block of the pilus of 
 
Neisseria gonorrhoeae
 
(gonococcus [GC]). GC pilin is known to carry a disaccharide O-glycan, which has an 
 
 
 
Gal
attached to the O-linked GlcNAc by a 1–3 glycosidic bond. In this report, we describe the
cloning and characterization of the GC gene, pilus glycosyl transferase A (
 
pgtA
 
), which encodes
the galactosyl transferase that catalyzes the synthesis of this Gal–GlcNAc bond of pilin glycan. A
homopolymeric tract of Gs (poly-G) is present in the 
 
pgtA
 
 gene of many GC strains, and this
 
pgtA
 
 with poly-G can undergo phase variation (Pv). However, in many other GC, 
 
pgtA
 
 lacks
the poly-G and is expressed constitutively without Pv. Furthermore, by screening a large num-
ber of clinical isolates, a significant correlation was observed between the presence of poly-G in
 
pgtA
 
 and the dissemination of GC infection. Poly-G was found in 
 
pgtA
 
 in all (24 out of 24) of
the isolates from patients with disseminated gonococcal infection (DGI). In contrast, for the
vast majority (20 out of 28) of GC isolated from uncomplicated gonorrhea (UG) patients, 
 
pgtA
 
lacked the poly-G. These results indicate that Pv of 
 
pgtA
 
 is likely to be involved in the conver-
sion of UG to DGI.
Key words:
 
Neisseria gonorrhoeae
 
 • pilus • DGI • poly-G tract • glycosyl transferase
 
Introduction
 
An estimated 650,000 cases of gonorrhea, caused by 
 
Neisseria
gonorrhoeae
 
, occur annually in the United States (1). Gono-
 
coccus (GC)
 
* 
 
also causes additional complications such as
pelvic inflammatory disease (PID), disseminated gonococ-
cal infection (DGI), and ophthalmia neonatorum. Al-
though most GC infections are uncomplicated and con-
 
fined to genitourinary tract epithelium, in 
 
 
 
1% of
gonorrhea cases the bacteria gain access to systemic circula-
tion and cause disseminated diseases (2). In addition, HIV-
infected women exhibit an increased risk of contracting
DGI (3, 4). However, not much is known about the mech-
anism of conversion of uncomplicated gonorrhea (UG) to
the more complicated DGI.
Neisserial pili are filamentous surface structures that are
polymeric fibers consisting mainly of pilin protein (
 
pilE
 
gene product). Pilus antigenic variation, resulting from fre-
quent changes of the pilin amino acid sequence due to
RecA-mediated exchanges between silent partial pilin
genes (
 
pilS
 
) and the pilin expression locus (
 
pilE
 
), is impor-
tant for GC to evade human immuno surveillance and may
 
also play a role in determining tissue tropism (5–7). In addi-
tion, the GC pili undergo phase variation (Pv), the revers-
ible interconversion between predominantly piliated and
nonpiliated states (8, 9). A few mechanisms, some of which
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Abbreviations used in this paper:
 
 DATDH, 2,4-diacetimido-2,4,6-
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with pulse amperometric detection; IP, immunoprecipitation; IPTG, iso-
 
propyl-
 
 
 
-
 
d
 
-thiogalactopyranoside; LOS, lipooligosaccharide; MC, men-
ingococcus; MS, mass spectrometry; ORF, open reading frame; 
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, pi-
lus glycosyl transferase A; PID, pelvic inflammatory disease; poly-G/C,
homopolymeric tract of Gs or Cs; Pv, phase variation; UG, uncompli-
cated gonorrhea. 
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are similar to the antigenic variation, have been proposed
to explain pilus Pv (10). Studies with human volunteers
(11, 12), as well as with organ (13, 14) and tissue (15, 16)
culture systems, have confirmed the important role of GC
pili in establishing gonorrheal infection.
Several studies have clearly established that pilin of 
 
N.
gonorrhoeae
 
 (17, 18) and the related pathogen 
 
Neisseria men-
ingitidis
 
 (meningococcus [MC]; reference 19) are glyco-
sylated. A high resolution x-ray crystallographic study (18) on
GC strain MS11 (variant C30) reported the presence of an
O-linked disaccharide Gal
 
 
 
1–3GlcNAc–O (see Fig. 1) on
the pilin protein. Pili of MC are glycosylated in the same
region of the pilin molecule but instead of GlcNAc, they
generally contain the unusual sugar, 2,4-diacetimido-2,4,6-
trideoxyhexose (DATDH), as the O-linked residue (19).
Also, unlike the GC glycan, the MC O-glycan is usually a
trisaccharide, Gal
 
 
 
1–4Gal
 
 
 
1–3DATDH–O. Nevertheless,
other alternative forms of glycans, as well as a total lack of
glycosylation, have been reported from some strains of
both GC and MC (20, 21).
The homopolymeric tracts of Gs or Cs (poly-G/C) with
seven or more consecutive G/C sequences are found
within many structural genes of GC and MC (22), includ-
ing those encoding glycosyl transferases involved in both
lipooligosaccharide (LOS) biosynthesis (23–26) and cap-
sule biosynthesis (27). Similar sequence features also occur
in the promoter regions of genes encoding the outer
membrane proteins Opc (28) and PorA (29), as well as in
the signal peptide of PilC protein (30). These poly-G/C
tracts mediate a high frequency (10
 
 
 
2
 
–10
 
 
 
4
 
) of reversible
on/off switching of gene expression. This poly-G/C–medi-
ated Pv of the aforementioned genes likely provides ad-
vantages to the bacteria in different niches of the human
body. The MC 
 
pglA
 
 gene (31), which synthesizes the
Gal
 
 
 
1–3DATDH bond (similar to GC Gal
 
 
 
1–3GlcNAc
bond shown in Fig. 1) of MC pilin glycan, also contains a
poly-G tract.
Here, we report the identification of a gene, pilus glyco-
syl transferase A (
 
pgtA
 
), which codes for the glycosyl trans-
ferase that forms the Gal
 
 
 
1–3GlcNAc linkage of GC pilin
glycan. We also provide a detailed analysis of the PgtA ac-
tivity by various techniques of molecular genetics, bio-
chemistry, and mass spectrometry (MS). We have found
that in many GC, 
 
pgtA
 
 occurs in a phase-variable allelic
form that carries a poly-G tract. However, in other strains
and isolates, 
 
pgtA
 
 lacks the poly-G and is expressed consti-
tutively without any variation. The implications of the
presence and absence of 
 
pgtA
 
 variability on GC pathogene-
sis, particularly in relation to the causation of systemic ver-
sus uncomplicated gonococcal diseases, were examined.
 
Materials and Methods
 
Chemicals, Enzymes, Bacterial Strains, and Plasmids.
 
Unless other-
wise indicated, all chemicals were obtained from Sigma-Aldrich
and all enzymes were obtained from New England Biolabs, Inc.
For all cloning, 
 
Escherichia coli
 
 XL-1Blue MRF
 
  
 
(Stratagene) cells
were used as the host. GC strains, plasmids, and oligonucle-
 
otides used in this study are listed in Table I. GC was grown us-
ing media and conditions as previously described (24, 32), and 2
 
 
 
g/ml erythromycin were added for selection when needed.
 
Recombinant DNA Methods.
 
Based on FA1090 genome se-
quence data, a pair of 
 
pgtA
 
-specific oligonucleotide primers,
PgtA1 and PgtA2 (Table I and see Fig. 2 A), was designed. 
 
 
 
ZapII
vector–based (Stratagene) GC genomic libraries (25) of strain
FA1090, MS11A, F62, and 15253 were screened by colony hy-
bridization using the random prime-labeled PgtA1-PgtA2 ampli-
con according to published protocols (25, 33). Positive clones
from the GC libraries were converted to their corresponding
pBluescript II SK
 
  
 
phagemids by using the manufacturer’s in vivo
excision protocol. Thus, phagemids ppgtA1, ppgtA2, ppgtA3,
and ppgtA4 (Table I and see Fig. 2 A) were derived from F62,
MS11A, FA1090, and 15253 libraries, respectively. Additionally,
ppgtA5 was constructed by cloning the PgtA3-PgtA4 amplicon
of FA1090 into EcoRV-BamHI–digested pBluescript II KS
 
 
 
.
The 
 
pgtA
 
 gene of ppgtA5 was knocked out by introducing
 
ermC
 
 
 
, an erythromycin resistance cassette (24, 25). The resulting
plasmid was designated as ppgtA-erm (Table I and see Fig. 2 A).
ppgtA-erm DNA was transformed (34) into strains FA1090,
MS11A, F62, and 15253 for disruption of 
 
pgtA
 
 in these GC. The
transformants were selected on GC agar containing 2 
 
 
 
g/ml
erythromycin. Later, the polar 
 
ermC
 
  
 
cassette was replaced with
its nonpolar derivative, as we recently described (35). The
knockouts were verified by PCR reactions using the aforemen-
tioned oligonucleotides by DNA sequencing of the PCR prod-
ucts and by Southern hybridization. The PCR conditions were
the same as previously described (36). DNA was sequenced and
oligonucleotides were synthesized by the Rockefeller University
Protein/DNA Technology Center (New York, NY). Sequences
of poly-G/C tracts were verified using a previously published
method (23). The sequence analyses were performed using a La-
sergene software package (DNASTAR). For sequence alignment,
the Jotun-Hein algorithm of the MegAlign program of this pack-
age was used.
To examine Pv of 
 
pgtA
 
, a few 
 
pgtA-
 
FLAG reporter chimera
were made (Table I and see Figs. 2 A and 8) using a pCMVTag4
vector kit (Stratagene). Several COOH-terminal translational fu-
sions of the FLAG (DYKDDDDK) epitope tag with the GC 
 
pgtA
 
open reading frame (ORF) were constructed. For this purpose,
PgtA5-PgtA6 amplicons from the GC strains FA1090 (
 
pgtA
 
 with
11-G poly-G) and F62 (without poly-G) were cloned into the
three pCMVTag4 vectors using the SacI and EcoRV sites. As de-
signed, the cloning of both FA1090 and F62 
 
pgtA
 
 inserts in the
pCMVTag4b produced “in-frame” PgtA–FLAG fusions, ppgtA–
F1a and ppgtA–F2a, respectively, due to the merger of 
 
pgtA
 
ORF with the functional ORF of FLAG. The cloning of
the same FA1090 and F62 PgtA5-PgtA6 amplicons into
pCMVTag4a or pCMVTag4c generated the “out of frame”
PgtA–FLAG chimera, ppgtA–F1b and ppgtA–F2b, respectively,
due to the fusion of the 
 
pgtA
 
 ORF with the nonfunctional ORFs
of FLAG. All of the constructs were checked by appropriate
PCRs, restriction analyses, and DNA sequencing. In addition, the
reaction of commercially available anti-FLAG mAb M2 (Sigma-
Aldrich) was used to distinguish the in-frame FLAG fusions from
the out of frame ones by Western blotting (see below).
 
Extraction and Purification of Pilin Samples from GC Strains.
 
Initially, pilin was extracted from GC according to previously
published protocols (37–39) with minor modifications. Bacterial
inocula from single, heavily piliated colonies were streaked
densely onto 50 100 
 
  
 
15–mm plates containing GC medium.
18–22 h later, the bacterial colonies were checked for piliation 
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and harvested with cotton swabs into 50 ml ice-cold 0.15 M eth-
anolamine-HCl, pH 10.1. All subsequent operations were per-
formed at 4
 
 
 
C. Bacteria were homogenized for 10 min at 2,500
rpm in a Sorvall Omnimixer. The suspension was centrifuged at
12,000 
 
g
 
 for 30 min to remove the sheared bacteria. Pilin was
 
precipitated by adding solid ammonium sulfate to 10% saturation,
collected by centrifugation at 12,000 
 
g
 
 for 45 min, and then the
pellet was dissolved in 5 ml ethanolamine-HCl buffer. Insoluble
contaminants were removed by centrifugation at 13,000 
 
g
 
 for 60
min and the supernatant was dialyzed overnight against Tris-
 
Table I.
 
A List of GC Laboratory Strains, Oligonucleotide Primers, and Plasmids Used
 
GC strains Poly-G in 
 
pgtA
 
Isolated from Site of isolation Accession no. Reference
FA1090
 
 
 
, (11 G, on) DGI Cervix AF485418 (73)
15253
 
 
 
, (14 G, on) DGI Blood AF485418 (74)
UUI
 
 
 
, 
 
 
 
 (10 G, off) DGI Blood AF485418 (75) and 
 
a
 
KH4318
 
 
 
, 
 
 
 
 (11 G, on) ? ? AF485418 ?
M20
 
 
 
, 
 
 
 
 (11 G, on) ? ? AF485418 ?
RT397
 
 
 
, 
 
 
 
 (11 G, on) ? ? AF485418 ?
F62 — UG Female urethra AF485419 (73)
MS11A/C — UG ? AF485419 (38)
1291 — UG Male urethra AF485419 (76) and 
 
b
 
R10 — UG Male urethra AF485419 (38)
M13Ison — UG ? AF485419
 
c
 
140Ison — UG ? AF485419
 
c
 
Pgh3-2 — UG ? AF485419 (38)
Primers Direction 59 Extension Sequence Position Reference
PgtA1 F - CGGCGGAACAGGTTAAG 1,802 bp of ppgtA1 insert Fig. 2 A
PgtA2 R - TCGATCAGGAAGCCGTTG 1,999 bp of ppgtA1 insert Fig. 2 A
PgtA3 F ATGATCGGATCC AATTCGGTGACTACGGCTG 684 bp of ppgtA1 insert Fig. 2 A
PgtA4 R ATACCGGAATTC ACCACCTTGTTTACGCCTT 2,279 bp of ppgtA1 insert Fig. 2 A
PgtA5 F ATGTAAGAGCTC AATTCGGTGACTACGGCTG 684 bp of ppgtA1 insert Fig. 2 A
PgtA6 R ATACCGGATATC TCGATCAGGAAGCCGTTG 1,999 bp of ppgtA1 insert Fig. 2 A
Plasmids Insert description Reference
ppgtA1 3,356 bp F62 
 
pgtA
 
 insert starting 1,138 bp upstream of start codon Fig. 2 A
ppgtA2 MS11A 
 
pgtA
 
 DNA equivalent to 1,205–2,268 bp of ppgtA1 insert Fig. 2 A
ppgtA3 FA1090 
 
pgtA
 
 DNA equivalent to 1,445–3,345 bp of ppgtA1 insert Fig. 2 A
ppgtA4 15253 
 
pgtA
 
 DNA equivalent to 684–2,668 bp of ppgtA1 insert Fig. 2 A
ppgtA5 FA1090 PgtA3-PgtA4 amplicon cloned in pBluescript II KS
 
 
 
Fig. 2 A
ppgtA5-erm An XmaI-BsaWI 
 
ermC
 
 
 
 (24) fragment cloned in AgeI site of ppgtA5 to knockout 
 
pgtA
 
Fig. 2 A
ppgtA-F1a
FA1090 PgtA5-PgtA6 amplicon cloned in pCMVTag4b. In-frame COOH-terminal fusion
of FLAG epitope tag with the Pv
 
  
 
(11G) 
 
pgtA
 
. Fig. 2 A
ppgtA-F1b Identical insert as above cloned in pCMVTag4c. Out of frame Pv
 
  
 
pgtA
 
–FLAG fusion. Fig. 2 A
ppgtA-F2a F62 PgtA5-PgtA6 amplicon cloned in pCMVTag4b. In-frame fusion of FLAG with Pv  pgtA. Fig. 2 A
ppgtA-F2b Identical insert as above cloned in pCMVTag4a. Out of frame FLAG fusion with the Pv  pgtA. Fig. 2 A
Restriction sites in the primers are underlined. ppgtA1, ppgtA2, ppgtA3, and ppgtA4 are from GC libraries made by cloning partially digested
fragments of genomic Tsp509I in pBluescript II SK . Except in ppgtA1, DNA inserts are in the direction of lacZ in these plasmids.  , present;  ,
absent; ?, unknown;  , approximate data; DGI, disseminated gonococcal infection; UG, uncomplicated gonorrhea; Pv , phase-variable pgtA; Pv ,
pgtA that expresses constitutively without any variation; F, forward or in the direction of pgtA; R, direction reverse to F. The number of Gs in each
poly-G and expression status of pgtA are indicated in parentheses.
aZ. McGee, bM. Apicella, and cC. Ison, personal communications.150 Role of pgtA in Gonococcal Pathogenesis
saline, pH 8.0 (0.05 M Tris-HCI and 0.15 M NaCl). The crystals
formed were collected by centrifugation at 12,000 g for 30 min
and the pellet was dissolved in ethanolamine-HCl buffer.
Because such semipurified pilin preparations carry LOS con-
tamination (39), we performed 16.5% tricine SDS-PAGE (40)
for separating pilin protein from the LOS. Two identical gels of
pilin samples were run in a Mini-protean (Bio-Rad Laboratories)
apparatus. One of the two gels was subjected to silver staining
(41) to check the separation of the two biomolecules. The other
gel was used for the isolation of separated pilin. This gel was
stained with reversible zinc stain (Bio-Rad Laboratories) and the
bands of pilin were located. Each pilin band was then cut from
the gel and destained. Thereafter, pilin was extracted from the
gel slices by spinning the crushed slices through an Ultrafree-DA
cartridge (Millipore). This purified pilin was subjected to 16.5%
tricine SDS-PAGE analysis and silver staining. Although the
stained pilin showed no trace of LOS at this stage, the pilin sam-
ples that were run in the parallel gel were subjected to one more
cycle of gel purification to reduce the possibility of LOS contam-
ination. These samples were examined by MS to confirm the ab-
sence of contamination. Later, these doubly purified pilin prepa-
rations were used for Western analysis and monosaccharide
composition determination.
Determination of Galactosyl Transferase Activity. The enzymatic
assessment for the galactosyl transferase activity of PgtA was per-
formed using a standard radioactive galactosyl incorporation as-
say, which has been used in previous investigations of bacterial
glycosylation (42–44). Using similar methods, the membrane
fractions of E. coli XL1-Blue host cells harboring the plasmids
containing the GC pgtA gene were examined for their ability to
catalyze the incorporation of radioactive Gal because this frac-
tion is known to be the source for bacterial galactosyl trans-
ferases. Similar membrane fractions from E. coli XL1-Blue strain
carrying no plasmid or carrying only the cloning vector, pBlue-
script II KS , were used as controls. The galactosyl transferase
activity of the pgtA knockout plasmid, ppgtA5-erm, was also
measured.
Bacterial cultures from mid-log phase (OD600   0.8) were har-
vested and resuspended in 50 mM Tris-HCl, pH 8.0, containing
30 mM magnesium acetate and 2 mM dithiothreitol (buffer A).
Bacteria were lysed using a sonicator cell disrupter (model W-220F;
Heat Systems-Ultrasonics) equipped with a microtip. Five con-
secutive 10-s pulses at setting 7 were applied under ice-cold con-
ditions. Unbroken cells and nuclear cell debris were then
removed by centrifugation at 5,000 g for 10 min at 4 C. Mem-
branes were collected as pellets from cell-free lysate by ultracen-
trifugation at 180,000 g for 1 h at 4 C and resuspended in buffer
A. The protein content of each membrane fraction was measured
using the DC protein assay (Bio-Rad Laboratories). Using mem-
brane fractions containing 800  g total proteins, each galactosyl
transfer reaction was performed in a final volume of 100  l con-
taining buffer A and 45,000 cpm [14C]UDP galactose (Perkin-
Elmer) substrate. After incubating the samples for 1 h at 37 C, the
incorporation of radioactivity into lipid intermediates was mea-
sured. 900  l chloroform/methanol (2:1) was added to stop the
reaction and extract the lipid-linked intermediates according to
the method of Osborn et al. (44). The radioactivity incorporated
into the intermediates was measured in a liquid scintillation
counter (2200 CA TRI-CARB; Packard Instrument Co.). The
enzymatic activity of the membrane fraction prepared from the
culture carrying ppgtA5 plasmid was also measured after induc-
tion at mid-log phase (OD600   0.8) by adding 5 mM isopropyl-
 -d-thiogalactopyranoside (IPTG) for 1 h.
Western Blot Analysis. For the characterization of the pgtA
mutation,   100 ng wild-type MS11A pilin and  500 ng
MS11ApgtA pilin were added to wells in a 10% Bis-Tris
NuPAGE gel (Novex) run in an electrophoresis chamber (XCell
II; Novex). 10  l SeeBlue (Novex) prestained marker was used as
the mol wt standard and 10  l of 1 mg/ml mouse laminin
(Sigma-Aldrich) was added per lane as the positive control for
monitoring GSL1-B4 and anti- Gal reactions. Electrophoresis
was performed according to the manufacturer’s protocols. West-
ern transfer was then performed using the XCell II (Novex)
module. After transfer, Immobilon-P (Millipore) polyvinylidene
difluoride membrane was cut into three pieces. The first piece
was treated with the mouse anti–GC pilin mAb 1E8/G8 (pro-
vided by M.S. Blake, Baxter Healthcare Corporation, Columbia,
MD; reference 45), the second with the  Gal-specific biotiny-
lated lectin GSL1-B4 (Vector Laboratories), and the third with a
human anti– Gal polyclonal Ab (provided by X. Chen, Wayne
State University, Detroit, MI; reference 46). For each of these
primary Ab/reactant reagents, goat anti–mouse IgG, streptavidin,
or goat anti–human IgG was used, respectively, as the secondary
Ab/reagent. The blots were developed using Western Blue
(Promega) alkaline phosphatase substrate according to the manu-
facturer’s instructions.
For the Western analysis of the PgtA-FLAG chimera, similar
methodologies of electrophoresis and transfer as described above
were used. However, the mAb used in this case was anti-FLAG
M2 (Sigma-Aldrich). In addition, the positive control for M2 re-
action was a firefly luciferase–FLAG fusion, pTag4lux–FLAG
(Stratagene).
Accurate Molecular Mass Determination of GC Pilin Proteins by
MS. This analysis was performed according to our previously
published immunoprecipitation (IP)/MS protocol (47). In this
experiment, the antipilin mAb, 1E8/G8 (45), was used for the IP
of GC pilin. 5  l semipurified preparation of pilin (containing
 5  g protein) was incubated overnight with 200  l hybridoma
culture supernatant of mAb 1E8/G8 and 3  l protein A/protein
G plus agarose beads (Oncogene Research Products). For this in-
cubation, a modified dilution buffer (140 mM NaC1, NOG
[0.1% N-octyl-glucoside], 10 mM Tris-HCl, pH 8.0) was used.
The beads were precipitated and washed twice with 500  l ice-
cold dilution buffer. The beads were then washed with 500  l
Tris buffer (10 mM Tris-HCl, pH 8) and 500  l deionized dis-
tilled water, respectively. Lastly, pilin protein was extracted from
the precipitated beads using 2  l formic acid/water/isopropanol
(1:4:4, vol/vol/vol), which contained saturated 4HCCA ( -cyano-
4-hydroxycinnamic acid) and the mass calibrant, bovine insulin
(Sigma-Aldrich). The molecular masses of pilin proteins were
measured by a matrix-assisted laser desorption/ionization time of
flight mass spectrometer (PerSeptive Biosystems).
Monosaccharide Composition Analyses of GC Pilin Glycans. This
was performed by the high performance anion exchange chroma-
tography with pulse amperometric detection (HPAE-PAD)
method. The procedure was performed with a slight modification
of a previously published HPAE-PAD protocol (48). A DX-500
HPLC workstation from the Dionex Corporation was used for
this purpose. Purified pilin protein was subjected to TFA (2 N)
hydrolysis and HCl (6 N) hydrolysis at 100 C for 4 h to release
the sugars as monosaccharides. TFA hydrolysis yields accurate
values for neutral sugars but not for amino sugars whereas the re-
verse is true for HCl hydrolysis (48). Therefore, both hydrolysis
protocols were applied together in most monosaccharide analyses
for the correct determination of sugar composition. During acid
hydrolysis, GlcNAc and GalNAc are converted quantitatively to151 Banerjee et al.
GlcN and GalN due to deacylation and therefore are represented
by two peaks in the PAD chromatograph, respectively. After
each acid hydrolysis, the hydrolysate was purified by a passage
through a Microcon-SCX (Millipore) cartridge, which is known
to retain the amino acids. The hydrolysates were then passed
through a PA-10 (Dionex) column in a DX-500 machine for
monosaccharide analysis. The PA-10 column was attached to an
amino trap guard column and an anion trap column (standard as-
sembly for monosaccharide analysis of glycoproteins). The eluent
was 18 mM NaOH with the flow rate of 1 ml/min. The experi-
ments were performed at room temperature.
Southern Hybridization. The protocol used is a minor modifi-
cation of our previous protocols (24, 49). The probe, a random
prime-labeled PgtA1-PgtA2 amplicon (Table I and see Fig. 2 A),
was made using the ECL kit (Amersham Biosciences) according
to the manufacturer’s instructions. GC genomic DNA was iso-
lated as previously performed by Moxon et al. (50). BsrBI was
used for the digestion of genomic DNA and Southern hybridiza-
tion was performed on Hybond-N  nylon membranes (Amer-
sham Biosciences) according to the manufacturer’s manual.
Colony Immunoblotting for Examination of pgtA Pv. The proto-
col used for this experiment is similar to that described by Sam-
brook et al. (33). E. coli XL-1Blue cultures were grown in Luria-
Bertani broth to log phase. Cultures were then diluted to obtain
 103–104 bacteria/ml and 10 or 20  l of the dilutions were
plated per spot on Luria-Bertani agar plates. The plates were in-
cubated at 37 C with 5% CO2 for 18–24 h. The colonies were
transferred, lysed, and immunoblotted onto nitrocellulose filters
strictly adhering to the protocol of Sambrook et al. (33). The col-
onies were detected using M2 anti-FLAG mAb and the Western
Blue (Promega) detection kit.
Results
Cloning of pgtA from GC. The cloning of pgtA from
GC was an offshoot of our previous work (25) involving
the discovery of the LOS biosynthetic gene (lgtG) whose
product forms the  1–3-galactosyl bond between the LOS
  chain Glc and the second core heptose. Before we started
the search for lgtG, it was known that the product of the E.
coli LPS synthetic gene, rfaG, synthesizes a Glc 1–3Hep
bond that is somewhat similar to the Glc 1–3Hep bond of
GC LOS that joins the   chain to the core. To identify the
GC gene involved in joining the   chain to the LOS core,
we searched for homologues of E. coli RfaG in the GC ge-
nome. A TBLASTN (51) search of the GC strain FA1090
genome sequence (using the University of Oklahoma
server) yielded two putative GC ORFs that showed a simi-
lar level of homology to RfaG ( 30% homology over a
stretch of 130 amino acids; unpublished data). One of the
rfaG homologues from GC, lgtG, was found to be involved
in the formation of the Glc 1–3Hep bond that joins the  
chain to the core of LOS (25). However, the knockout of
the other ORF (now designated pgtA) did not alter the
LOS phenotypes of GC (unpublished data).
Later, a BLAST search on Genbank using GC ORF as
the query yielded the RfpB peptide of Shigella dysenteriae
(sequence data are available from Genbank/EMBL/DDBJ
under accession no. AAC60480) as the best score ( 50%
identity over the full-length of both proteins; see Fig. 2 B).
RfpB was known to form a Gal 1–3GlcNAc bond in the
LPS of S. dysenteriae (52, 53). It was also known that GC
pilin carries an O-linked Gal 1–3GlcNAc (18). Thus, we
hypothesized that this GC ORF (pgtA) could be forming
the Gal 1–3GlcNAc bond of GC pilin glycan by transfer-
ring the Gal to the O-linked GlcNAc. Therefore, we
named it pilin glycosyl transferase A. The DNA sequences
of the pgtA genes from strains FA1090 and MS11A are
available from Genbank/EMBL/DDBJ under accession
nos. AF485418 and AF485419, respectively.
After this, a report describing MC pglA (31) was
published that proposed that PglA synthesizes the
Gal 1–3DATDH bond of MC pilin glycan. The Gal 1–
3DATDH bond of MC pilin glycan is similar to the
Gal 1–3GlcNAc bond (Fig. 1) of GC pilin glycan in spite
of the significant difference between the sugars GlcNAc
and DATDH. We found that the sequence identity be-
tween MC PglA and GC PgtA is  96% (Fig. 2 B), which
indicates a very strong conservation.
By searching various finished and unfinished bacterial
genome data banks, we identified several more ORFs that
show homology to pgtA (unpublished data). Among these
frames and of particular interest is a strong homologue from
Pseudomonas aeruginosa that has 36% identity over the full-
length of GC pgtA (Fig. 2 B).
Examination of Galactosyl Transferase Activity of PgtA. It
has recently been shown that glycosyl transferase activities
that modify several surface proteins of gram-negative bac-
teria, including flagellin and pilin, display strong sequence
conservation with glycosyl transferases participating in LPS
biosynthesis (31, 54). This indicates a general glycosylation
machinery for the synthesis of all bacterial surface glycans
that likely uses conserved intermediates. Thus, the various
gram-negative surface glycosyl transferases generally display
glycosyl transferase activity when cloned by plasmid vectors
into E. coli host strains (42, 43). This cloned transferase ac-
tivity, like the LPS transferases, resides in the membrane
fraction of E. coli cells. Therefore, one well-known test for
bacterial galactosyl transferase involves the assessment of ra-
dioactive incorporation from [14C]UDP Gal into lipid in-
termediate carriers, usually undecaprenoyl phosphoryl ac-
ceptors, by the membrane fraction of E. coli (42). This assay
has been used in the past for the characterization of several
bacterial galactosyl transferases (42–44) and we adopted a
similar approach to demonstrate the galactosyl transferase
activity of PgtA.
Figure 1. Current model of gly-
cosylation of pilin of N. gonorrhoeae.
Vertical bar on the right, pilin
polypeptide; Gal, galactose;
GlcNAc,  N-acetyl-glucosamine;
Ser63, O-glycosylated serine at posi-
tion 63 of GC pilin polypeptide.152 Role of pgtA in Gonococcal Pathogenesis
The Gal transferase activity of PgtA was examined in the
background of the cloning host strain, E. coli XL1-Blue
(Fig. 3). The activities of the membrane fractions of the
XL1-Blue bacteria carrying the plasmids with a functional
pgtA gene (ppgtA1 and ppgtA5) were found to be  10-
fold higher compared with that of the control hosts carry-
ing no plasmid or the pBluescript II KS  vector. The
bacteria with the cloned pgtA knockout (ppgtA5-erm) dis-
played a similar level of activity compared with the
controls. Notably, all assays were performed using equal
amounts of membrane fraction as well as identical reaction
conditions (Materials and Methods). Both forms of pgtA,
the constitutive (ppgtA1) and the phase-variable (ppgtA5),
were tested. Moreover, to obtain a clearer understanding of
the association of the Gal transferase with PgtA function,
we decided to measure the galactosyl incorporation by the
bacteria carrying ppgtA5 after the addition of IPTG. An in-
duction of pgtA expression by IPTG was expected in this
case because of the lack of a transcriptional stop between
the Lac promoter and the pgtA promoter. A part of the
pgtA mRNA would likely be transcribed from the induc-
ible Lac promoter of the cloning vector, pBluescript II
SK . Indeed, a roughly twofold increase in activity was ob-
served after the IPTG induction (Fig. 3), further confirm-
ing the specific association of the Gal transferase activity
with the PgtA function.
Lectin and Ab Reactions of MS11A and MS11ApgtA Pilin
Proteins. Previously, by performing Western blots with
MC pilin, Hamadeh et al. (55) observed that MC pilin re-
acts with the  Gal-specific lectin GSL1-B4 as well as with
anti- Gal human polyclonal Abs. We decided to test pilin
proteins of GC strain MS11A and its isogenic pgtA mutant
with these two reagents, particularly because no specific
mAb is currently available that recognizes the  Gal epitope
of GC pilin glycan. Among the GC strains, MS11 was cho-
sen for this analysis so that our data can be comparable to
Figure 2. Molecular genetic char-
acterization of the GC pgtA and its
encoded activity. (A) Maps of the
different GC DNA fragments that
were cloned for analysis of the pgtA
from various strains. Solid arrows,
ORFs; vertical bars, poly-G tracts;
open arrows, the location and direc-
tion of the oligonucleotide primers.
(B) Alignment of PgtA homologues.
Amino acid sequence of PgtA from
GC strain FA1090 (GCPgtA) is
compared with that of PglA from
MC (MCPglA), RfpB of S. dysente-
riae (ShigellaRfpB), and a function-
ally unknown ORF of P. aeruginosa
(PsPgtAhlog). For this alignment,
Jotun-Hein algorithm of the
MegAlign program (DNASTAR)
was used. The boxes represent se-
quence conservation. The tract of
four consecutive glycines (residues
246–249) of PgtA, which corre-
spond to the poly-G sequence, is
marked by a thick solid line over it.153 Banerjee et al.
the past studies of GC pilin glycan, which extensively used
different variants of strain MS11. Also, the variant A of this
strain (MS11A) is used as it produces a smaller LOS that
runs farther separated from the pilin in SDS-PAGE and
thus lessens the chance of LOS contamination of pilin dur-
ing the gel extraction.
Western blots (Fig. 4) showed a specific reaction of
GSL1-B4 with the wild-type MS11A pilin. This lectin did
not react with the pilin of the isogenic pgtA mutant. Simi-
larly, the anti- Gal human polyclonal Ab only reacted
with the wild-type MS11A pilin and not with the
MS11ApgtA pilin. The antipilin polypeptide mAb, 1E8/
G8, was used as a control to monitor pilin proteins. Mouse
laminin, well known to have  Gal, was used as a positive
control for the GSL1-B4 as well as for the anti- Gal reac-
tion. In addition, neither the lectin nor the anti- Gal
Ab reacted with LOS molecules of either MS11A or
MS11ApgtA (unpublished data), further demonstrating the
specific nature of this interaction.
MS of Pilin Proteins from MS11A and MS11ApgtA. IP/
MS analysis was performed on pilin proteins obtained from
MS11A and its isogenic pgtA knockout mutant. The major
peak ([M H]  ion) representing the wild-type pilin from
MS11A had a molecular mass of 17,934.7 daltons (Fig. 5).
The molecular mass of the corresponding peak from the
isogenic pgtA mutant was 17,772.5 daltons. The mass dif-
ference (162.2 daltons) corresponded well with the mass of
a hexose sugar molecule (162.1 daltons). Doubly charged
peaks ([M 2H]2 ) were observed from both the MS11A
(8,957.1 daltons) and MS11ApgtA (8,874.4 daltons) sam-
ples. The difference (82.7 daltons), when multiplied by 2,
also yields a value (165.4 daltons) that corresponds well
with a loss of hexose in the case of the mutant.
Additionally, the observed relative molecular mass of the
pilin samples tallied well with the predicted molecular
weight of pilin proteins derived from the amino acid se-
quences of MS11 pilins (18). The internal standard, human
insulin peptide (Mr   5,734.60), worked well in both spec-
tra. Another peak (Mr    8,548) was observed not only in
both spectra but also in the control (no pilin) spectrum
containing only the reagents (unpublished data). Therefore,
this peak likely comes from either the mAb used during the
IP step or another reagent.
Monosaccharide Composition of Pilin Glycans of MS11A and
MS11ApgtA. We determined the monosaccharide com-
position of the purified pilin proteins of GC strain MS11A
and its isogenic pgtA mutant by the HPAE-PAD. The
HPAE-PAD chromatograms are shown in Fig. 6. A sub-
stantial decrease in the relative Gal content of pilin is ob-
served in the pgtA mutant when compared with the wild-
type MS11A. This result would be expected from the
postulated role of PgtA in transferring a Gal to the O-linked
GlcNAc of GC pilin. However, we also observed other
sugars present in chromatograms that cannot be accounted
for by the current model of the disaccharide pilin glycan
(Fig. 1). These observations possibly stem from the fact that
the GC pilus glycan is likely to be more elaborate and
complex than the current model.
Presence or Absence of Poly-G in pgtA of GC Laboratory
Strains. DNA sequences of pgtA from the ppgtA plasmids
and amplicons (Table I and Fig. 2 A) revealed the presence
of a phase-variable poly-G tract region in the pgtA ORF of
GC laboratory strains FA1090, 15253, UU1, KH4318,
RT397, and M20. An 11-G poly-G was found in the pgtAs
of all these strains except for 15253, which has a 14-G
Figure 3. Galactosyl transferase activity in the membranes of E. coli
XL1-Blue–expressing GC pgtA. The columns indicate the incorporation
of radioactive galactosyl moiety from [14C]UDP Gal into the lipid-linked
intermediates catalyzed by different E. coli membrane fractions expressing
various plasmids. E. coli XL1-Blue (without any plasmid) and its deriva-
tive with cloning vector pBluescript II KS  (pKS ) were used as controls
for this enzymatic assay. The same host strain with plasmids ppgtA1 and
ppgtA5 were assessed for their ability to transfer Gal under the same con-
dition. The specificity of galactosyl transferase activity of PgtA from
ppgtA5 was also tested by induction with IPTG (5 mM), as part of this
pgtA transcript is likely transcribed from the Lac promoter of the cloning
vector pKS . The activity of ppgtA5-erm (pgtA knockout) was also eval-
uated. All assays were done in duplicate and standard deviations are
shown by error bars (not visible on all columns).
Figure 4. Western analysis of MS11A and MS11ApgtA pilins using an-
tipilin mAb 1E8/G8, GSL1-B4 lectin, and polyclonal human anti– Gal
Ab, respectively. Mouse laminin was used as a positive control for
GSL1-B4 and anti- Gal reactions. Lanes marked MW contain SeeBlue
prestained molecular weight marker (Novex).154 Role of pgtA in Gonococcal Pathogenesis
poly-G (Fig. 7 A). Both 11-G and 14-G tracts correspond
to the “on” frame of pgtA. In these pgtA alleles, if the num-
ber of Gs increases by one (frameshift by  1), a nonfunc-
tional PgtA results with a premature termination of ORF at
a position 91 amino acids less than the full-length PgtA.
Similarly, if the number of Gs decreases to 10 (frameshift
by  1), the ORF terminates prematurely at 126 amino ac-
ids ahead of the normal stop. The number of Gs in the
poly-G of the pgtAs of strains FA1090 (these sequence data
are available from Genbank/EMBL/DDBJ under accession
no. AF485418) and 15253 was determined unambiguously
because these alleles were sequenced from plasmids carry-
ing cloned GC DNA inserts. Also, the on status of the 11-G
pgtA of FA1090 has been confirmed by direct examina-
tion of PgtA-FLAG chimera (Fig. 8 A). In contrast, for
strains UU1, KH4318, RT397, and M20, the numbers of
Gs in the poly-G of pgtA (Table I) should be considered
tentative, as these data numbers were obtained by sequenc-
ing PgtA1-PgtA2 amplicons after PCR. PCR is well
known to produce shifts in a poly-G/C during amplifica-
tion and the numbers of Gs in some of these poly-Gs might
have changed from those actually present in the poly-G of
the genomic DNA. For the same reason, the indicated on/
off status of pgtA of these strains (Table I) should also be
considered ambiguous because these designations are based
on the determination of the number of Gs in the poly-G
tract sequences after PCR.
Notably, the aforementioned phase-variable poly-G tract
is not present in the pgtAs of GC strains MS11A, MS11C,
F62, 1291, R10, M13Ison, 140Ison, and Pgh3-2. Among
these strains, the pgtA DNA sequences of only MS11A
(these sequence data are available from Genbank/EMBL/
DDBJ under accession no. AF485419) and F62 were deter-
mined from plasmid clones. For the rest of the strains, pgtA
sequencing was performed using PgtA1-PgtA2 amplicons.
All of these pgtA alleles have nearly identical sequences that
correspond to a nonvariable and constitutively on form of
the gene. In these pgtAs, a GGGAGCGGGG sequence is
found instead of the poly-G tract of the phase-variable al-
lele (Fig. 7 A). The important differences found in the
nonvariable allele are the presence of an A instead of the
Figure 5. Matrix-assisted laser desorption/ionization time of flight MS
study of pilins obtained from GC strain MS11A (top) and its isogenic mu-
tant MS11pgtA (bottom). Bovine insulin peptide (molecular mass of
5,734.60 daltons) was added as the internal calibrant. Molecular masses of
the major peaks are indicated.
Figure 6. Monosaccharide composition analysis of pilins obtained from
GC strain MS11A and its isogenic mutant, MS11ApgtA. The top chro-
matogram is of a standard mixture of monosaccharides containing 2 nmol
of each component. The other chromatograms are hydrolysates of indi-
cated GC pilins. Glc, glucose; Gal, galactose; Man, mannose; GalN, ga-
lactosamine; GlcN, glucosamine; C, coulomb.155 Banerjee et al.
fourth G, a C for the sixth G, and an absence of the last G
of the poly-G. Near the poly-G, a few other changes were
also observed between the two alleles as shown in Fig. 7 A.
The rest of the sequence for the two types of pgtA is almost
identical (unpublished data). The ORFs of both alleles are
of similar length and apparently use the same start and stop
codons. The pgtA that lacks poly-G carries an extra BsrBI
restriction enzyme site (GAGCGG) in its GGGAG-
CGGGG sequence.
Because the sequencing of G-rich DNA tracts is not al-
ways reliable, we verified the presence/absence of poly-G
in pgtA by performing Southern hybridization of BsrBI-
digested genomic DNAs of different GC strains. A labeled
PgtA1-PgtA2 amplicon from strain FA1090 was used as a
probe. In the Southern analysis (Fig. 7 B), the strains that
were suggested to have GGGAGCGGGG showed two hy-
bridizing bands indicating the presence of the extra BsrBI
site. We observed that MS11A, F62, 1291, M13Ison,
140Ison, and R10 yielded the two-band pattern whereas
FA1090, 15253, KH4318, M20, and UU1 showed a single
band. This result confirmed the DNA sequencing data ob-
tained from these strains.
Presence or Absence of Poly-G in pgtA of GC Clinical Iso-
lates. We reviewed the clinical origin of the GC labora-
tory strains (Table I) that were divided into two categories
based on the presence or absence of the poly-G tract in the
pgtA gene. This analysis indicated an interesting correlation
between the presence or absence of the poly-G with dif-
ferent disease phenotypes of gonococcal infection. F62,
MS11A, 1291, R10, M13Ison, 140Ison, and Pgh3-2 (the
strains lacking a poly-G in pgtA) were originally isolated
from patients with uncomplicated infection. On the con-
trary, FA1090, 15253, and UU1 were obtained from DGI
patients. This finding indicated the possibility that the DGI
isolates bear a poly-G in pgtA whereas UG isolates do not.
To further test this hypothesis, we examined the presence/
absence of the poly-G tract in pgtA of many well-charac-
terized patient isolates from three different gonococcal dis-
ease phenotypes: DGI, UG, and PID. PgtA1-PgtA4 ampli-
cons from these isolates were analyzed by BsrBI RFLP as
well as by DNA sequencing. The results showed a presence
of the poly-G tract in all 24 (100%) DGI strains (Table II).
In contrast, only 8 out of 18 ( 44%) PID isolates (Table
III) and 8 out of 28 ( 29%) UG isolates (Table IV) con-
tained the poly-G. It is noteworthy that in every case
where poly-G was not found in pgtA, the GGGAGC-
GGGG sequence was found instead. No other sequence
has been observed to substitute poly-G in any GC strain or
isolate. In comparison, the poly-G tract of pgtA was ob-
served to be quite variable among the clinical isolates. The
number of Gs in the poly-G varied from 9 to 20. How-
ever, the numbers of Gs present in the poly-G of pgtA (and
the consequent on/off status of pgtA) bear no particular
correlation with the different disease phenotypes, the sites
of isolation, or the gender of the patients. Nevertheless, it
must also be noted that the numbers of the Gs present in
the poly-G tracts (as well as the indicated on/off phase sta-
tus of pgtA) are only provisional. Again, this is for the same
Figure 7. Presence and absence of the poly-G tract in
the  pgtA genes of several laboratory strains of GC. (A)
Alignment of the pgtA DNA sequences from N. gonorrhoeae
strains carrying (top four sequences) and not carrying
(bottom six sequences) the phase-variable poly-G. The
amino acid translation is given above or below the se-
quences. The BsrBI site, only present in the bottom se-
quences, is marked by an underline. Vertical bars, the
identity of bases; dots, gaps in alignment; bold letters, the
mismatches found within the poly-G tract region. (B)
Southern analysis of BsrBI-digested GC genomic DNAs.
On left, the picture of the DNA gel stained with ethidium
bromide and on the right, the Southern autoradiograph are
shown. A fluorescence-labeled 1-kb ladder (Amersham
Biosciences) was used as the molecular weight marker. The
source strain of each genomic DNA is indicated above the
relevant lane.156 Role of pgtA in Gonococcal Pathogenesis
reason (i.e., use of the PCR sequencing method that may
shift the number of Gs in poly-G) as described previously
in relation to the poly-G sequence determination of some
GC lab strains. Furthermore, DNA was isolated from these
clinical isolates after multiple in vitro passage and stocking
of the bacteria. Thus, in these clinical isolates, both in vitro
growth and DNA sequence determination by PCR se-
quencing may have caused changes in the number of Gs in
the poly-G tract compared with the number present in or-
ganisms at the time and site of original isolation. Thus, the
number of Gs for these isolates’ pgtA poly-G may not al-
ways be accurate.
It is worthy to note that in our DGI collection, there are
two isolates (8 and 13 in Table II) that are designated as
having originated from more than one clinical site in the
same patient. In these cases, GC was obtained from one of
the indicated sites and not from all of the sites of the same
patient. For example, in sample 13, B/U would mean that
the GC tested was isolated either from the blood or the ure-
thra of a particular patient. In this case, the clinical records
show that the organisms were isolated from two sites of the
patient’s body but the bacterial stock only indicated the pa-
tient’s name and not the site of isolation. Therefore, it was
concluded that the organisms could have originated from
any of the sites listed. It certainly does not mean that there
are two separate isolates with the same number of Gs in
poly-G of pgtA that were obtained from the blood and the
urethra, respectively, from one individual.
Poly-G–mediated Pv of GC pgtA. The presence of poly-G
tracts was observed in the pgtA genes of many GC strains
and isolates. Because other poly-G carrying neisserial genes
were previously found to be phase variable, the pgtA that
had a poly-G was expected to show Pv. However, the pgtA
lacking the poly-G (having a GGGAGCGGGG stretch in-
stead) was predicted to be expressed constitutively without
any variation based on Markov’s model (22). Nevertheless,
the latter GC-rich stretch may have also had a small possi-
bility of displaying Pv because of two tandem short runs of
Gs. Thus, it was necessary to verify the phase variability of
both forms of pgtA.
Moreover, Pv of these alleles could not be tested using
the polyclonal human anti– Gal Ab or the  Gal-specific
GSL1-B4 lectin because the colony blots using these re-
Figure 8. Poly-G–mediated Pv of the GC pgtA gene. (A) Western
analysis of various PgtA–FLAG COOH-terminal fusion proteins ex-
pressed in E. coli XL-1 Blue host. On left, the Coomassie-stained gel
shows the proteins present in the lysates of various E. coli hosts that carry
different PgtA–FLAG fusions or controls. The corresponding Western
blot, which was performed using anti-FLAG mAb M2, is shown on the
right. The extreme lanes, marked MW, contain molecular weight
marker. A firefly luciferase–FLAG fusion expressed from the plasmid,
pTag4lux-FLAG (Stratagene), is the positive control for M2 reaction.
The lysates from the cells carrying the vectors, pTag4b and pYUB631,
are the two negative controls. ppgtA–F1a and ppgtA–F1b carry the in-
frame and the out of frame fusions of FA1090 PgtA and FLAG, respec-
tively. The in-frame and out of frame F62 PgtA-FLAG chimera are made
by ppgtA–F2a and ppgtA–F2b, respectively. ppgtA–F1aFS1 is a putative
phase variant (see below) of ppgtA–F1a resulting from a frameshift in pgtA
poly-G. (B) The colony blot for the identification of potential phase vari-
ants of FA1090 pgtA cloned in E. coli XL-1 Blue host. The XL-1 Blue
colonies carrying the positive control, pTag4lux-FLAG, are at the top
spot. The negative control colonies, carrying pCMVTag4b vector, are at
the bottom. The colonies of bacteria carrying the in-frame pgtA–FLAG
(ppgtAF1a) and the out of frame pgtA–FLAG (ppgtAF1b) fusions are
shown on the right and left, respectively. The potential phase-variant col-
onies are marked by arrows. (C) The DNA sequence of the poly-G tract
of a potential phase variant (ppgtA–F1aFS1) obtained from the bacteria
with the in-frame fusion (ppgtAF1a). The sequences from both DNA
strands are shown with the leading strand data presented on the top. The
direction of the transcription of pgtA for each sequence is indicated by an
arrow. The G/Cs of the poly-G/C tract of pgtA are numbered in the di-
rection of transcription.157 Banerjee et al.
agents yielded high background even for the pgtA mutants.
These background reactions likely resulted from the non-
specific interactions of other surface antigens of GC, for
example the  Gal epitope of the alternative   chain of
LOS. Therefore, we planned to test Pv of both alleles us-
ing a reporter-based approach that used a commercial
mAb, knowing that such Abs were shown to work with
colony blots.
A COOH-terminal FLAG epitope tag (DYKDDDK)
was translationally fused with the pgtA ORFs in the fol-
lowing manner (also refer to Materials and Methods).
First, FLAG fusions were made with the poly-G carrying
FA1090 pgtA to obtain an in-frame (ppgtA–F1a) as well as
an out of frame chimera (ppgtA–F1b). Similarly, in-frame
(ppgtA–F2a) and out of frame FLAG (ppgtA–F2b) fusions
were constructed with the F62 pgtA, which lacks a poly-G.
All of the aforementioned constructs were expressed in
E. coli XL1-Blue hosts. As we expected, all of the in-
frame fusions reacted with anti-FLAG mAb M2 and all
out of frame fusions failed to do so (Fig. 8 A). The posi-
tive control, a FLAG fusion with firefly luciferase
(pTag4lux–FLAG) and the two negative controls, vectors
pTag4b and pYUB631, behaved as we anticipated. The
two negative controls were included to test if the unex-
pressed FLAG (lacking any promoter) of pTag4b pro-
duced any reaction with M2. pYUB631 does not contain
any FLAG sequence.
The immunoblots of the XL1-Blue colonies having the
in-frame fusion, ppgtA–F1a, yielded a few potential phase
variants that failed to react with mAb M2 (Fig. 8 B). Sim-
ilarly, potential phase variants showing positive M2 reac-
tion were observed among M2 nonreactive colonies
carrying the out of frame fusion (ppgtA–F1b). These
potential variants arose with frequencies of  10 2. Four
of the potential phase-variant clones that were obtained
from the ppgtA–F1a colonies were sequenced from both
DNA strands. All were found to carry 10 Gs in their poly-G
tract, a number that is 1 G less (a  1 frameshift) than
Table II. Examination of pgtA Poly-G Tract in GC Clinical 
Isolates Obtained from Patients with DGI
GC isolate
Poly-G
in pgtA
Site
of isolation
Sex
of patient Reference
1  ,   (14 G, on) B F (77)
3  ,   (14 G, on) P F (77)
4  ,   (10 G, off) B M (77)
5  ,   (14 G, on) B M (77)
8  ,   (15 G, off) B/C/P/R F (77)
10  ,   (13 G, off) P F (77)
11  ,   (14 G, on) U M (77)
13  ,   (15 G, off) B/U M (77)
14  ,   (17 G, on) C F (77)
21  ,   (17 G, on) C F (77)
25  ,   (16 G, off) C F (77)
27  ,   (14 G, on) B M (77)
41  ,   (12 G, off) SF F (77)
43  ,   (14 G, on) SF M (77)
47  ,   (11 G, on) C F (77)
48  ,   (11 G, on) C F (77)
49  ,   (16 G, off) C F (77)
Kb  ,   (11 G, on) U F This studya
Tc-1  ,   (14 G, on) SF F This studya
Tc-2  ,   (15 G, off) ? F This studya
Bu  ,   (17 G, on) C F This studya
Aj  ,   (18 G, off) SF F This studya
Dj  ,   (17 G, on) SF ? This studya
Jj  ,   (11 G, on) ? F This studya
C, cervix; B, blood; U, urethra; SF, synovial fluid; P, pharynx; R,
rectum; M, male; F, female;  , present; ?, unknown;  , approximate
data; /, alternative sites of isolation (see Results). The number of Gs in
each poly-G and expression status of pgtA are indicated in parentheses.
It must also be noted that the on/off status of pgtA expression is tentative
as this is predicted based on the numbers of Gs in the poly-G as
determined by PCR sequencing.
aStrains taken from our collections that have not previously been re-
ported.
Table III. Presence and Absence of Poly-G Tract in GC Clinical 
Isolates Obtained from Patients with PID
Isolate Poly-G in pgtA Reference
PID 1 — (78)
PID 2  ,   (15 G, off) (78)
PID 6-1  ,   (14 G, on) This studya
PID 8  ,   (11 G, on) (78)
PID 17 — (78)
PID 18 — (78)
PID 20 — (78)
PID 22-1 — This studya
PID 302 — (78)
PID 305  ,   (15 G, off) (78)
PID 305-1  ,   (15 G, off) This studya
PID 332 — (78)
PID 334 — (78)
PID 335 — (78)
PID 336-1 — This studya
Ar  ,   (16 G, off) This studya
Au  ,   (17 G, on) This studya
Br  ,   (16 G, off) This studya
All isolates are from cervix.  , present;  , absent;  , approximate data.
The number of previously published isolates are identical to that used in
the cited reference. The number of Gs in each poly-G and expression
status of pgtA are indicated in parentheses. It must also be noted that the
on/off status of pgtA expression is tentative as this is predicted based on
the numbers of Gs in the poly-G as determined by PCR sequencing.
aStrains taken from our collections that have not previously been re-
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that of the poly-G of the parent ppgtA–F1a. The se-
quencing results from both strands of one of these phase
variants, ppgtA-F1aFS1, is shown in Fig. 8 C. The M2 re-
action of the ppgtA–FS1 fusion protein is shown in Fig. 8
A. Notably, the blots of the ppgtA–F2a- and ppgtA–F2b-
carrying colonies did not yield any potential variants (un-
published data), possibly due to a lack of poly-G in the
F62 pgtA.
Discussion
In this study, we report the cloning and characterization
of a GC pilin glycan biosynthetic gene that codes for a ga-
lactosyl transferase, which forms the  -glycosidic linkage
between C3 of GalNAc and C1 of the  Gal (Fig. 1). We
named this gene pgtA (pilus glycosyl transferase A) adhering
to the convention of other GC glycosyl transferases (24, 25,
56), particularly because we unambiguously demonstrated
the enzyme encoded by it to be a galactosyl transferase. We
first suspected this activity in this gene product because of
its strong homology with the RfpB protein of Shigella,
which has been shown to be the transferase that catalyzes
the formation of a Gal 1–3GlcNAc bond in LPS O-anti-
gen. The use of human anti– Gal antibodies and GSL1-B4
lectin, and Western analyses of the pilin proteins of GC
strain MS11A and its isogenic pgtA mutant, allowed a pre-
liminary confirmation of our hypothesis. These two  Gal-
specific reagents reacted with wild-type MS11A pilin but
not with the pilin of MS11ApgtA. In addition, MS studies
demonstrated a clear loss of a hexose due to the pgtA mu-
tation. HPAE-PAD–based monosaccharide composition
analysis of pilin proteins provided the final confirmation of
the proposed PgtA activity by demonstrating a quantitative
loss of Gal in the pgtA mutant.
GC PgtA demonstrates very high homology ( 95%
identity) with MC PglA (31), which has been proposed to
synthesize the MC pilin Gal 1–3DATDH bond, a linkage
analogous to that of Gal 1–3GlcNAc of GC pilin. How-
ever, the proposed substrate molecules for the two enzymes
(GlcNAc for PgtA and DATDH for PglA) are quite differ-
ent. Also, it should be noted that the  1,3 galactosyl trans-
ferase activity of PglA has yet to be shown unequivocally.
Nevertheless, the clear characterization of pgtA-encoded
 1,3 galactosyl transferase supports the proposed activity of
PglA (31). Interestingly, the most remarkable difference
between pglA and pgtA is that based on the presence of
poly-G. The former always seems to have Pv as it is found
with poly-G all the time, whereas the latter can either un-
dergo Pv or constitutively express the glycosyl transferase
activity depending on the presence or absence of the
poly-G. Furthermore, although no pathogenic implication of
PglA has been indicated in MC pathogenesis yet, here we
report a clear role for PgtA in GC pathogenesis. Therefore,
a reevaluation of pglA might be needed to understand its
role in MC pathogenesis. Lastly, it is also possible that PglA
and PgtA may each act on both types of substrates (carrying
DATDH or GlcNAc) and synthesize either type of pilin
glycan depending on the specific background provided by
different strains of MC and GC.
Notably, GC strains can be grouped into two categories
based on the phenotype of phase variability of the pgtA
gene. Sequence analysis demonstrated that pgtAs from cer-
tain GC strains and clinical isolates carried a poly-G tract,
and that the number of Gs of this poly-G varied widely
(between 9 and 20) from one isolate to another. In con-
trast, pgtA from other GC strains and isolates does not carry
the variable poly-G tract but a GGGAGCGGGG sequence
Table IV. Presence and Absence of Poly-G in GC Isolates from 
Patients with UG
Isolate
Poly-G
in pgtA
Sex
of patient
Site
of isolation
131a —M U
227a —M U
386a —M U
405a —M U
420a —M U
490a —M U
510a —M U
517a —M U
517109a —F C
538a  ,   (17 G, on) M U
543a —M U
543103a —F C
545a —M U
553a  ,   (18 G, off) M U
553630a  ,   (11 G, on) F C
575a —M U
577a  ,   (10 G, off) M U
577123a  ,   (13 G, off) F C
582a —M U
582125a —F C
598a  ,   (14 G, on) M U
659a —M U
PID 011b  ,   (9 G, off) M U
PID 022b —M U
PID 023a —M U
PID 032a —M U
PID 036a  ,   (20 G, on) M U
PID 037a —M U
Three-digit strains are from male patients with urethritis and
corresponding six-digit (starting with the same three digits) strains are
from their female contacts. The “PID 0” series strains are from male
partners of PID patients.  , present;  , absent; M, male; F, female; U,
urethra; C, cervix. The number of Gs in each poly-G and expression
status of pgtA are indicated in parentheses. The reference used is this
study. It must also be noted that the on/off status of pgtA expression is
tentative as this is predicted based on the numbers of Gs in the poly-G
as determined by PCR sequencing.
aStrains taken from our collections that have not previously been re-
ported, and bstrains reported in a study (78) that is also referenced in
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instead, which differs from an analogous poly-G tract by
only two bases. Still, the former allele of pgtA, but not the
latter, was expected to be phase variable because poly-G/C
tracts with seven or more G/Cs can mediate Pv (22). Us-
ing PgtA–FLAG fusions and colony blotting analyses, we
demonstrated that the pgtA carrying poly-G is phase vari-
able, but the allele lacking poly-G is expressed constitu-
tively without any variation. Thus, GC pgtA is found in
two mutually exclusive forms: one possessing and the other
lacking Pv.
Our results indicate a possible significance for the pres-
ence or absence of the phase-variable poly-G tract in terms
of GC pathogenesis. We observed that most GC associated
with local infection only (uncomplicated inflammatory dis-
ease or PID in women) lack poly-G in pgtA. PID isolates
may have the poly-G–bearing pgtA or the poly-G–lacking
allele. However, all DGI-causing bacteria that we tested
carried phase-variable pgtA. Poly-G–mediated Pv of pgtA
may be advantageous for a GC isolate that disseminates for
several reasons. One might be that anti- Gal IgGs are the
most abundant Abs ( 1% of total IgG population) in hu-
man sera (57) and turning off pgtA may help DGI isolates
avoid these. In addition, Pv is known to increase the reper-
toire of neisserial antigens that often mimic human antigens
and therefore may enhance tissue tropism of these bacteria
(56, 58). Similarly, Pv of pilin glycan is likely to produce
alternative glycoforms and therefore may lead to the ex-
pansion of potential host targets for GC that have dissemi-
nated. However, the nature of potential alternative pilin
glycans having phase-variable pgtA in GC strains has yet to
be determined, because such pilin glycans have never been
characterized. Future experiments will require analysis of
the pilin glycans strains that have phase-variable pgtA (such
as GC strain FA1090).
Although previous studies have associated several pheno-
types with DGI, the reason only a small percentage of un-
treated UG patients, and virtually no PID patients, develop
DGI remains largely unknown (unpublished data). Clearly,
serum resistance facilitates the systemic spread of GC by
aiding survival in blood and can arise by several mecha-
nisms (2). In addition, the arginine-hypoxanthine-uracil
auxotype, porin 1A expression, and a peptidoglycan hydro-
lase gene (atlA) have been reported to correlate with DGI
(59–61). Although each of these factors is found in a much
higher proportion of DGI isolates than in UG or PID iso-
lates, none shows absolute correlation with DGI. Our anal-
ysis showed that all (24 out of 24) DGI isolates tested car-
ried phase-variable pgtA. DGI might be facilitated by
multiple bacterial factors, none of which alone may be suf-
ficient to cause dissemination.
Like phase-variable pgtA, pgtA lacking Pv may have its
own advantages. This allele may help GC cause local infec-
tion because it is found in most UG (and PID) isolates and
it may be relevant to examine whether a direct intercon-
version of these alleles is possible. Estimates from the 1970s
suggest that  1% of local gonorrhea proceeds to DGI (2).
Although hypothetical, a DGI organism with a poly-G
tract in pgtA could be directly selected from its counterpart
that carries the corresponding nonhomopolymeric se-
quence, such a selection in vivo would require at least two
point mutations when considering the normal frequency of
mutational events. Nonetheless, the frequency of base
changes (particularly for the second change, which would
generate a full poly-G) in the GGGAGCGGGG sequence
of the constitutive pgtA allele can be significantly higher
than the normal mutational rate of GC, due to this stretch’s
close resemblance to a poly-G tract.
A comparative analysis of neisserial genomes (strains
MC58, Z2491, and FA1090) by Saunders et al. (22) indi-
cated the possible existence of a few genes that can be
phase variable in one organism but not in another (62).
Similarly, our study has shown pgtA to be a gene that exists
in a phase-variable form in some strains of GC but not in
others. To our knowledge, this is the first demonstration of
a gene that can occur in both phase-variable and constitu-
tive forms. This suggests the possibility that a gene might
confer greater advantage to one strain of a pathogenic spe-
cies as a “constitutive” gene, but to another strain of the
same species as a “contingency” gene (63). The presence of
the contingency allele of pgtA in DGI isolates would sup-
port the notion that these strains need greater adaptability
in the more diverse and changing environment encoun-
tered at different systemic sites (e.g., blood, joints, skin, and
occasionally the central nervous system and endocardium).
In contrast, under perhaps the more “constant” environ-
ment of local genitourinary sites, the selection pressure for
the contingency allele might be lessened. In this situation, a
constitutive expression of the gene may be acceptable, or
even preferred, if other benefits ensue.
Interestingly, from our search of existing databases, we
observed poly-G tracts in numerous bacterial pathogens
whose genomes have already been or are currently being
sequenced (unpublished data). It is possible that poly-G–
mediated Pv plays a role in the mechanism of pathogenesis
in a number of bacteria. In addition, bacterial surface struc-
tures, particularly protein structures including the pili of
other pathogenic bacteria, are increasingly being shown to
be glycosylated (64–68). In particular, the pgtA homologue
in P. aeruginosa is especially significant because both pilus
and flagella from Pseudomonas are known to be glycosylated
(64, 54). Future studies of bacterial surface glycans and their
effects on Pv may yield important information concerning
global pathogenic mechanisms.
Several types of glycosylation, present and absent, have
been seen in different strains and variants of both GC and
MC (17–21). Organizational variation of the pgl gene clus-
ter among different MC strains (69, 70) also illustrates the
degree of this diversity. Protein folding may influence gly-
cosylation (71) and even a single amino acid change in a
polypeptide may alter the glycosylation pattern (72). Diver-
sification of glycosylation of neisserial pilus may stem from
antigenic variation of pilin. Different pilin antigens may re-
cruit separate sets of glycosyl transferases to produce distinct
pilin glycosylation patterns. Therefore, synthesis of neisser-
ial pilin glycan may involve yet unknown glycosylation en-
zymes. Notably, our HPAE-PAD analysis (Fig. 6) detected160 Role of pgtA in Gonococcal Pathogenesis
novel sugars in MS11A pilin that were not described by
our proposed model (unpublished data). A multiplicity of
neisserial pilin glycoforms may arise because of involve-
ment of phase-variable biosynthetic genes. As expected
from this emerging diversity, the role of neisserial pilin gly-
cans in pathogenesis of infection may take on an additional
level of complexity.
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